AbiertoNCT04055818Ver en ClinicalTrials.gov ↗⚑ Reportar un problema con este anuncio

A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

Mostrando el original en inglés

Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell Disease

Afección específica por raza/etnia

Fase

PHASE1

Inscripción

20 (estimado)

Rango de edad

18 Years to —

Sexo

ALL

Resumen

A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).

Mostrando el original en inglés

Afecciones estudiadas

Sickle Cell Disease

Patrocinadores

EpiDestiny, Inc.Principal

National Heart, Lung, and Blood Institute (NHLBI)Colaborador

National Institutes of Health (NIH)Colaborador

Ubicaciones del estudio

University of Illinois at Chicago College of Medicine

Chicago, Illinois

Lani Krauz, CONTACT